Dhkgfrqeulkgfhiowqgasasaa SK Nla SN KN Aslk La S Al JH Lash Lanlksbaasd Asd Antacids

dhkgfrqeulkgfhiowqgasasaA sk nla sn kn aslk la s al ;jh lash lanlksbaAsd asd ANTACIDS
Antacids are weak bases that react with gastric hydrochloric acid to form a salt and water. Their principal mechanism of action is reduction of intragastric acidity. Sodium bicarbonate (eg, baking soda, Alka Seltzer) reacts rapidly with hydrochloric acid (HCL) to produce carbon dioxide and sodium chloride. Formation of carbon dioxide results in gastric distention and belching. Unreacted alkali is readily absorbed, potentially causing metabolic alkalosis when given in high doses or to patients with renal insufficiency. Sodium chloride absorption may exacerbate fluid retention in patients with heart failure, hypertension, and renal insufficiency. Formulations containing magnesium hydroxide or aluminum hydroxide react slowly with HCl to form magnesium chloride or aluminum chloride and water. Because no gas is generated, belching does not occur. Metabolic alkalosis is also uncommon because of the efficiency of the neutralization reaction. Because unabsorbed magnesium salts may cause an osmotic diarrhea and aluminum salts may cause constipation, these agents are commonly administered together in proprietary formulations (eg, Gelusil, Maalox, Mylanta) to minimize the impact on bowel function. Both magnesium and aluminum are absorbed and excreted by the kidneys. Hence, patients with renal insufficiency should not take these agents long-term.
H2-RECEPTOR ANTAGONISTS
Chemistry & Pharmacokinetics Four H2 antagonists are in clinical use: cimetidine, ranitidine, famotidine, and nizatidine. All four agents are rapidly absorbed from the intestine. Cimetidine, ranitidine, and famotidine undergo first-pass hepatic metabolism resulting in a bioavailability of approximately 50%. Nizatidine has little first-pass metabolism. The serum half-lives of the four agents range from 1.1 to 4 hours. H2 antagonists are cleared by a combination of hepatic metabolism, glomerular filtration, and renal tubular secretion. Pharmacodynamics The H2 antagonists exhibit competitive inhibition at the parietal cell H2 receptor and suppress basal and meal-stimulated acid secretion in a linear, dose-dependent manner. They are highly selective and do not affect H1 or H3 receptors. The volume of gastric secretion and the concentration of pepsin are also reduced.
PROTON PUMP INHIBITORS

Chemistry & Pharmacokinetics Five proton pump inhibitors are available for clinical use: omeprazole, lansoprazole, rabeprazole, pantoprazole, and esomeprazole. Proton pump inhibitors are administered as inactive prodrugs. To protect the acid-labile prodrug from rapid destruction within the gastric lumen, oral products are formulated for delayed release as acid-resistant, enteric-coated capsules or tablets. After passing through the stomach into the alkaline intestinal lumen, the enteric coatings dissolve and the prodrug is absorbed. Proton pump inhibitors undergo rapid first-pass and systemic hepatic metabolism and have negligible renal clearance. Dose reduction is not needed for patients with renal insufficiency or mild to moderate liver disease but should be considered in patients with severe liver impairment. Although other proton pumps exist in the body, the H+,K+ ATPase appears to exist only in the parietal cell and is distinct structurally and functionally from other H+transporting enzymes. From a pharmacokinetic perspective, proton pump inhibitors are ideal drugs: they have a short serum half-life, they are concentrated and activated near their site of action, and they have a long duration of action. Pharmacodynamics In contrast to H2 antagonists, proton pump inhibitors inhibit both fasting and meal-stimulated secretion because they block the final common pathway of acid secretion, the proton pump. In standard doses, proton pump inhibitors inhibit 9098% of 24-hour acid secretion. When administered at equivalent doses, the different agents show little difference in clinical efficacy.
MUCOSAL PROTECTIVE AGENTS

1. Sucralfate Chemistry & Pharmacokinetics Sucralfate is a salt of sucrose complexed to sulfated aluminum hydroxide. In water or acidic solutions it forms a viscous, tenacious paste that binds selectively to ulcers or erosions for up to 6 hours. Sucralfate has limited solubility, breaking down into sucrose sulfate (strongly negatively charged) and an aluminum salt. Less than 3% of intact drug and aluminum is absorbed from the intestinal tract; the remainder is excreted in the feces. Pharmacodynamics A variety of beneficial effects have been attributed to sucralfate, but the precise mechanism of action is unclear. It is believed that the negatively charged sucrose sulfate binds to positively charged proteins in the base of ulcers or erosion, forming a physical barrier that restricts further caustic damage and stimulates mucosal prostaglandin and bicarbonate secretion. 2. Prostaglandin Analogs Chemistry & Pharmacokinetics The human gastrointestinal mucosa synthesizes a number of prostaglandins; the primary ones are prostaglandins E and F. Misoprostol, a methyl analog of PGE1 , has been approved for gastrointestinal conditions. After oral administration, it is rapidly absorbed and metabolized to a metabolically active free acid. The serum half-life is less than 30 minutes; hence, it must be administered 34 times daily. It is excreted in the urine; however, dose reduction is not needed in patients with renal insufficiency. Pharmacodynamics Misoprostol has both acid inhibitory and mucosal protective properties. It is believed to stimulate mucus and bicarbonate secretion and enhance mucosal blood flow. In addition, it binds to a prostaglandin receptor on parietal cells, reducing histamine-stimulated cAMP production and causing modest acid inhibition. Prostaglandins have a variety of other actions, including stimulation of intestinal electrolyte and fluid secretion, intestinal motility, and uterine contractions.

Dhkgfrqeulkgfhiowqgasasaa SK Nla SN KN Aslk La S Al JH Lash Lanlksbaasd Asd Antacids

Uploaded by

Copyright:

Available Formats

Dhkgfrqeulkgfhiowqgasasaa SK Nla SN KN Aslk La S Al JH Lash Lanlksbaasd Asd Antacids

Uploaded by

Document Information

Original Description:

Original Title

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

Dhkgfrqeulkgfhiowqgasasaa SK Nla SN KN Aslk La S Al JH Lash Lanlksbaasd Asd Antacids

Uploaded by

Copyright:

Available Formats

dhkgfrqeulkgfhiowqgasasaA sk nla sn kn aslk la s al ;jh lash lanlksbaAsd asd ANTACIDS

PROTON PUMP INHIBITORS

MUCOSAL PROTECTIVE AGENTS

You might also like